PriceTargets.com logo

Ambrx Biopharma - AMAM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.25
  • Forecasted Upside: 26.65%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$14.41 As of 06/8/2023 01:00 AM ET
▲ +0.73 (5.34%)

This chart shows the closing price for AMAM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ambrx Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMAM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMAM

Analyst Price Target is $18.25
▲ +26.65% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Ambrx Biopharma in the last 3 months. The average price target is $18.25, with a high forecast of $30.00 and a low forecast of $6.00. The average price target represents a 26.65% upside from the last price of $14.41.

This chart shows the closing price for AMAM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Ambrx Biopharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/1/2023OppenheimerInitiated CoverageOutperform$30.00Low
5/19/2023Cantor FitzgeraldInitiated CoverageOverweight$25.00Low
4/5/2023Robert W. BairdBoost TargetOutperform$11.00 ➝ $12.00Low
3/3/2023Robert W. BairdBoost Target$4.00 ➝ $11.00Low
2/27/2023The Goldman Sachs GroupBoost TargetNeutral$2.00 ➝ $6.00Low
10/19/2022Robert W. BairdLower Target$8.00 ➝ $4.00Low
9/21/2022Robert W. BairdLower Target$16.00 ➝ $8.00Low
5/24/2022The Goldman Sachs GroupLower TargetNeutral$6.00 ➝ $4.00High
4/6/2022Robert W. BairdInitiated CoverageOutperform$16.00High
2/28/2022The Goldman Sachs GroupInitiated CoverageNeutral$6.00Low
7/13/2021CowenInitiated CoverageOutperform$21.30High
7/13/2021Bank of AmericaInitiated CoverageBuy$26.00High
7/13/2021The Goldman Sachs GroupInitiated CoverageBuy$53.00High
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/10/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/10/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
Mentions as of
3/10/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2023
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Ambrx Biopharma logo
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The company's lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. It is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, the company is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $14.41
Low: $13.34
High: $14.73

50 Day Range

MA: $11.45
Low: $7.66
High: $14.97

52 Week Range

Now: $14.41
Low: $0.38
High: $15.29

Volume

445,820 shs

Average Volume

2,879,830 shs

Market Capitalization

$795.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Ambrx Biopharma?

The following Wall Street analysts have issued reports on Ambrx Biopharma in the last year: Cantor Fitzgerald, Oppenheimer Holdings Inc., Robert W. Baird, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for AMAM.

What is the current price target for Ambrx Biopharma?

4 Wall Street analysts have set twelve-month price targets for Ambrx Biopharma in the last year. Their average twelve-month price target is $18.25, suggesting a possible upside of 26.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting AMAM will reach $30.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $6.00 for Ambrx Biopharma in the next year.
View the latest price targets for AMAM.

What is the current consensus analyst rating for Ambrx Biopharma?

Ambrx Biopharma currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMAM will outperform the market and that investors should add to their positions of Ambrx Biopharma.
View the latest ratings for AMAM.

What other companies compete with Ambrx Biopharma?

Other companies that are similar to Ambrx Biopharma include Anavex Life Sciences, HilleVax, Immatics, Novavax and Allogene Therapeutics. Learn More about companies similar to Ambrx Biopharma.

How do I contact Ambrx Biopharma's investor relations team?

The company's listed phone number is 858-875-2400. The official website for Ambrx Biopharma is ambrx.com. Learn More about contacing Ambrx Biopharma investor relations.